Free EpiPen® campaign returns in response to overwhelming demand

Allergy New Zealand and Pub Charity revived success FundaPen campaign to deliver 3,355 free life-saving EpiPen® auto-injectors for patients with physician-diagnosed allergies who are at risk of anaphylaxis.

the
FundaPen2 the initiative follows the first campaign in 2019, which saw nearly 3,000 New Zealanders receive a free EpiPen® (adrenaline auto-injector).

Allergy New Zealand’s chief executive, Mark Dixon, said: “The life-changing campaign has been wholeheartedly supported by healthcare professionals and members of the allergy community, who have been calling for its repetition ever since. that it ended in 2020”.

Pub Charity CEO Martin Cheer says, “Pub Charity is proud to support the FundaPen2
initiative. We know from past experience what a positive contribution this can make to the lives of people with severe allergies, especially those on low incomes.

Life-saving EpiPens® only last 12-18 months, are not currently funded by PHARMAC, and can cost between $120 and $350 each. Over the past 17 years, Allergy New Zealand has filed eight applications for EpiPen® auto-injectors to be publicly funded through PHARMAC.

the FundaPen2 The campaign was made possible by a generous donation of $350,000 from Pub Charity to Allergy New Zealand. The national charity will buy 3,355 EpiPen® auto-injectors from Queenstown Pharmacy, which come from a New Zealand supplier, Viatris Ltd.

Mark Dixon says the return of
FundaPen2 will help meet an important need for New Zealanders at risk of anaphylaxis, whose families/whānau are struggling to purchase an EpiPen®. “We have received so much support for FundaPen from prescribers and the allergy community, our Facebook page received over 100,000 visits in the first 24 hours after the first public launch,” he says.

“In Australia, people at risk of anaphylaxis are now eligible for two funded adrenaline auto-injectors each year. In this country, none are funded, and the speed at which free EpiPens® have been adopted under FundaPen
shows us that there are significant unmet needs.

Through the original
FundaPen campaign, which was made possible by a $300,000 donation from Pub Charity, Allergy New Zealand was able to reach those least able to afford the life-saving drug. A total of 2,875 EpiPens® were distributed between November 2019 and August 2020.

“We continue to actively campaign for EpiPens® to be publicly funded, as it is in Australia,” says Mark.

For over 40 years, Allergy New Zealand has been improving the quality of life of New Zealanders living with allergies, providing evidence-based information and support. Allergy New Zealand receives no government funding and will not receive any financial benefit from the Pub Charity donation.

Eligible patients will be eligible for
FundaPen2 from Wednesday, February 9, 2022 while supplies last.

FundaPen2™ THE FACTS

  • EpiPen® auto-injectors are available through the FundaPen2 initiative from Wednesday, February 9, 2022.
  • To obtain one of the free EpiPen® auto-injectors, families will need to speak with their family doctor or prescriber.
  • 1 EpiPen® per eligible patient.
  • The exclusive distributor is Queenstown Pharmacy (www.AllergyPharmacy.co.nz)
  • Each recipient should receive training and education on the use of the EpiPen® and the management of their allergy to avoid anaphylaxis, from their prescriber.
  • The aim of Allergy New Zealand and Pub Charity is to ensure that as many eligible patients as possible benefit from the
    FundaPen2 initiative.
  • Once 3,355 FREE EpiPen® auto-injectors have been dispensed from the Queenstown Pharmacy, normal prescribing protocols, dispensing and fees will apply.

© Scoop Media

Comments are closed.